Scientists have discovered how extracellular vesicles maintain their structural integrity during cellular transport through blood vessels and bodily fluids, revealing a critical role for specialised ion channels that regulate internal conditions.
A breakthrough in chemical synthesis methodology offers pharmaceutical manufacturers a more environmentally sustainable approach to incorporating chlorine into drug compounds, with implications for both process efficiency and molecular modification.
Children’s Hospital of Philadelphia researchers have developed an advanced artificial intelligence model that can simultaneously identify and classify cells in complex tissue samples, potentially transforming how diseases are studied and diagnosed at the cellular level.
GlaxoSmithKline (GSK) has entered into an agreement to acquire Boston-based IDRx for up to $1.15 billion, securing rights to IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST). The deal comprises an upfront payment of $1 billion and a potential $150 million regulatory milestone payment.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Touchlight’s Hampton facility a Manufacturer’s Authorisation for Investigational Medicinal Products (MIA, IMP) licence, marking a significant advancement in synthetic DNA production. This certification enables the manufacture of Investigational Active Pharmaceutical Ingredients (API) and critical starting materials for Advanced Therapy Medicinal Products (ATMP).
Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific have announced a strategic partnership to optimise T cell expansion protocols, combining Terumo BCT’s Quantum Flex Cell Expansion System with FUJIFILM’s PRIME-XV T Cell Expansion Media. This collaboration addresses significant manufacturing challenges faced by cell therapy developers, particularly those in early-stage development.
Monheim-based Cube Biotech has acquired IBA Lifesciences in a strategic transaction that combines two significant players in protein research and production technologies. The acquisition, announced on 13 January 2025, creates an entity with enhanced capabilities in membrane protein production, purification, and stabilisation technologies.
Cambridge-based organ-on-chip (OOC) technology developer CN Bio has established a strategic partnership with Japanese distributor Primetech Corporation to expand access to its microphysiological systems throughout Japan. The collaboration arrives as the Japanese OOC market demonstrates significant growth potential, with projections indicating a market value of £22.1M by 2030, representing a compound annual growth rate of […]
Cambridge-based Abselion has secured £6.6 million in Series A financing to commercialise its Amperia protein analyser system, which enables rapid at-line quantification of antibodies, AAVs and other proteins from crude samples. The funding round was led by M Ventures, with participation from new and existing investors.
Two prominent European biospecimen and life sciences companies have combined to strengthen research capabilities across Europe and North America, marking significant expansion in biospecimen services and stem cell research sectors.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
